Sentences with phrase «circulating tumor cells in»

Frouws» team believe the drug may boost the immune system's ability to detect and destroy circulating tumor cells in the blood.

Immunicon Corporation (PI)($ 40,000 Total) 2001 - 2002 Longitudinal enumeration of circulating tumor cells in patients with metastatic breast carcinoma

Review Circulating Tumor Cells in the Parallel Invasion Model Supporting Early Metastasis Gerhard Hamilton, Barbara Rath Oncomedicine 2018; 3: 15 - 27.

Researchers have found a group of circulating tumor cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

For example, cancer cells floated above denser blood cells, which could allow clinicians to spot rare circulating tumor cells in a patient sample.

Currently, in another study, the researchers are focused on detecting circulating tumor cells in the blood of patients with a diagnosis of breast cancer.

Not exact matches

The other two major targets in the field, circulating tumor cells and exosomes, come with their own challenges.

«There was this initial thought that [circulating tumor cells] are only present at late stage,» says Sollier - Christen, but she notes that in the past year, several studies using more sensitive techniques have found such cells much earlier in tumor development, even before the tumor becomes visible by conventional imaging techniques.

«Circulating tumor cells have the advantage that they are... intact living cells,» says Michael Kazinski, senior director and head of global product management for sample technologies at Qiagen in Hilden, Germany.

Cancer cells can break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream, and grow in a distant focus (metastasize) in normal tissues elsewhere in the body.

The study team wanted to understand the particular traits of the tumor cells circulating in the blood and in the sites where the cancer has spread.

Metastatic cancer cells have the ability to break free from tissue, circulate in the blood stream, and form tumors all over the body, in a way acting like blood cells.

Now a team of researchers in China has developed a new microfluidic chip that can quickly and efficiently segregate and capture live circulating tumor cells (CTCs) from a patient's blood, with potential applications for cancer screenings and treatment assessments.

Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in the number of circulating tumor cells (CTCs) harboring increased copies of the ALK gene over the first two months of treatment was associated with increased progression - free survival.

«We wanted to utilize platelets» intrinsic tendencies to accumulate at wounds and to interact with circulating tumor cells, for targeted delivery of immune checkpoint inhibitors» said Gu, «Interestingly, we found the antibody can be promoted to release from activated platelets in the surgical site, due to generation of small platelet - derived microparticles upon the platelet activation.

«Despite the identification of circulating tumor cells (CTCs) and cell - free DNA (cfDNA) as biomarkers capable of providing clinically relevant information in cancer patients, at present their identification is not routinely used in clinical practice,» explains Silvia Morbelli, MD, PhD, of the IRCCS San Martino — IST National Cancer Research Institute and University of Genoa in Genoa, Italy.

In a study presented in the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F - fluorodeoxyglucose (FDG) PET / CT imaging to show that the amount of cell - free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyIn a study presented in the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F - fluorodeoxyglucose (FDG) PET / CT imaging to show that the amount of cell - free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyin the featured clinical investigation article of the November issue of The Journal of Nuclear Medicine, they used 18F - fluorodeoxyglucose (FDG) PET / CT imaging to show that the amount of cell - free tumor DNA circulating in the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyin the bloodstream correlates with tumor metabolism (linked to cancer aggressiveness), not tumor burden (amount of cancer in the bodyin the body).

In addition, while cfDNA correlated with tumor metabolism, no association was found with circulating tumor cells (CTCs).

A more abundant and less invasive source of tumor DNA may be cell free tumor DNA found circulating in the blood.

The size difference between tumor and healthy circulating DNA was initially discovered in animal tumor models created by inducing tumors with human cancer cells.

«This development has the potential to enable earlier detection of solid tumors through a simple blood draw by substantially improving our ability to detect very low quantities of circulating DNA derived from tumor cells,» says corresponding author Hunter Underhill, M.D., Ph.D., who initiated the research while in the lab of senior author Jay Shendure, M.D., Ph.D., a professor in genome sciences at the University of Washington.

«High concordance between EGFR mutations from circulating - free tumor DNA and tumor tissue in non-small cell lung cancer.»

Epidermal growth factor receptor (EGFR) mutations found in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.

Further research could test these cancer stem cell gene expression at the RNA and protein level in circulating tumor cells and biopsies from patients on trial.

The technique typically homes in on circulating - tumor DNA (ctDNA), genetic material that routinely finds its way from cancer cells into the bloodstream.

The results were published in the journal Lab on a Chip (Lab on a Chip 17 (19), 3291 - 3299) in an article called: «Magnetic particles assisted capture and release of rare circulating tumor cells using wavy - herringbone structured microfluidic devices.»

Adds Liu: «With metastatic cancers accounting for around 90 % of deaths from solid tumors, the hope is that one day a device that can enable the analysis of single tumor cells circulating in the blood could make a big difference in early diagnosis, detection and monitoring of numerous types of cancer, without invasive biopsies.»

Liu's «lab on a chip» is notable for its ability to not only capture tumor cells circulating in the blood, but to «release» those cells as well.

Liu has been perfecting a microfluidic device the size of two quarters that has the ability to catch and release circulating tumor cells (CTCs)-- cancer cells that circulate in a cancer patient's blood.

An additional advantage to the new subtyping is that it can be performed on tumor cells circulating in the blood.

The role of rebiopsy and repeat analysis in the setting of post-treatment relapse, along with testing of blood samples for mutations in circulating tumor cells, cell free tumor DNA, or exosomes will be considered.

«To answer these questions, one has to divide cancers into two groups: solid tumors that require the development of a blood supply to metastasize and enlarge, and soft tumors that may have circulating cells, as in leukemias.

In tumor - bearing mice, the researchers could monitor the real - time dynamics of circulating cancer cells released from a primary tumor.

Now, researchers reporting in the Cell Press journal Chemistry & Biology have developed a new method that allows investigators to label and track single tumor cells circulating in the blood.

In a study using mice, the researchers found that using Dox and TRAIL in the pseudo-platelet drug delivery system was significantly more effective against large tumors and circulating tumor cells than using Dox and TRAIL in a nano - gel delivery system without the platelet membranIn a study using mice, the researchers found that using Dox and TRAIL in the pseudo-platelet drug delivery system was significantly more effective against large tumors and circulating tumor cells than using Dox and TRAIL in a nano - gel delivery system without the platelet membranin the pseudo-platelet drug delivery system was significantly more effective against large tumors and circulating tumor cells than using Dox and TRAIL in a nano - gel delivery system without the platelet membranin a nano - gel delivery system without the platelet membrane.

Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize.

«This combination of features means that the drugs can not only attack the main tumor site, but are more likely to find and attach themselves to tumor cells circulating in the bloodstream — essentially attacking new tumors before they start,» says Quanyin Hu, lead author of the paper and a Ph.D. student in the joint biomedical engineering program.

Different types of tumors show a preference for specific organs and tissues; circulating breast cancer cells, for example, are likely to take root in bones, lungs, and the brain.

A recent clinical study by Dr. Antonarakis and colleagues showed that mCRPC in men who had AR - V7 in circulating tumor cells was resistant to the hormone drugs enzalutamide and abiraterone.

AR - V7 status was assessed through an experimental blood test that measures AR - V7 mRNA in circulating tumor cells.

Tumor cells circulating through the body in the bloodstream then take advantage of these cellular and molecular changes to lodge in the liver and form metastases.

These cells are thought to break off from the original tumor and circulate in the blood, and may be a sign of an aggressive tumor.

Once settled in the microwell, the circulating tumor cells were burst open and the proteins released from inside each cell were separated according to differences in size or mass.

«Circulating tumor cells — cells from a tumor that have escaped into the bloodstream with the potential to spread into other tissues — are extremely useful for assessing a patient's disease in order to select the most appropriate treatment,» said UBC mechanical engineering professor Hongshen Ma, the lead researcher.

The findings, published in Gastroenterology, suggest that circulating pancreas cells (CPCs) seed the bloodstream before tumors can be detected using current clinical tests such as CT and MRI scans.

The technique, described in Biomaterials, uses gold nanoparticles and Raman scattering, a technology previously developed by Qian and Nie for cancer cell detection (2007 Nature Biotech paper, 2011 Cancer Research paper on circulating tumor cells).

«Circulating tumor cells (CTCs) have been shed by the original tumor and entered the bloodstream — they can then form into new tumors if they lodge in distant tissue,» Wang says.

Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient.

Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient.

The authors also show that mice with tumors show an increase in the number of this type of circulating progenitor cells.